Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
- PMID: 17373920
- DOI: 10.1111/j.1365-2036.2006.03210.x
Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
Abstract
Background: The use of non-steroidal anti-inflammatory drugs (NSAIDs) is often associated with upper gastrointestinal symptoms such as heartburn and acid regurgitation.
Aim: To assess the efficacy of esomeprazole 20 and 40 mg for resolution of heartburn and acid regurgitation in continuous NSAIDs.
Methods: A post hoc analysis of five clinical trials was performed. Two identically designed, placebo-controlled, 4-week studies (NASA1, SPACE1) enrolled non-ulcer, NSAIDs-treated patients with upper abdominal pain, discomfort or burning. PLUTO and VENUS were identically designed, placebo-controlled, 6-month studies that enrolled patients at risk of NSAIDs-induced ulcers. Study 285 was an 8-week comparative study with ranitidine (300 mg/day) in patients with NSAIDs-induced gastric ulcers. Resolution of investigator-assessed heartburn and acid regurgitation was defined as symptom severity of 'none' in the last 7 days.
Results: In NASA1/SPACE1, heartburn resolved in 61% and 62% of patients taking esomeprazole 20 and 40 mg, respectively (vs. 36% on placebo, P < 0.001), and acid regurgitation resolved in 65% and 67% (vs. 48%, P < 0.001). Resolution of both symptoms was greater with esomeprazole than with placebo in PLUTO/VENUS (P <or= 0.001), and than with ranitidine in study 285 (P < 0.05 for esomeprazole 20 mg).
Conclusion: Heartburn and regurgitation are common in patients taking NSAIDs and esomeprazole is efficacious for resolution of these symptoms.
Similar articles
-
Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.Am J Gastroenterol. 2005 May;100(5):1028-36. doi: 10.1111/j.1572-0241.2005.41465.x. Am J Gastroenterol. 2005. PMID: 15842575 Clinical Trial.
-
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.Am J Gastroenterol. 2006 Apr;101(4):701-10. doi: 10.1111/j.1572-0241.2006.00499.x. Epub 2006 Feb 22. Am J Gastroenterol. 2006. PMID: 16494585 Clinical Trial.
-
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.Aliment Pharmacol Ther. 2009 May 1;29(9):967-78. doi: 10.1111/j.1365-2036.2009.03948.x. Epub 2009 Feb 3. Aliment Pharmacol Ther. 2009. PMID: 19210493 Clinical Trial.
-
Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.Expert Opin Pharmacother. 2007 May;8(7):975-88. doi: 10.1517/14656566.8.7.975. Expert Opin Pharmacother. 2007. PMID: 17472543 Review.
-
[Esophageal complications of non steroidal antiinflammatory drugs].Gastroenterol Clin Biol. 2004 Apr;28 Spec No 3:C58-61. doi: 10.1016/s0399-8320(04)95279-7. Gastroenterol Clin Biol. 2004. PMID: 15366675 Review. French.
Cited by
-
A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis.PLoS One. 2020 Jan 27;15(1):e0226184. doi: 10.1371/journal.pone.0226184. eCollection 2020. PLoS One. 2020. PMID: 31986170 Free PMC article. Clinical Trial.
-
Pain management in the geriatric population.Mo Med. 2014 Nov-Dec;111(6):508-11. Mo Med. 2014. PMID: 25665235 Free PMC article. Review.
-
Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.Drugs. 2009;69(1):51-69. doi: 10.2165/00003495-200969010-00004. Drugs. 2009. PMID: 19192936 Review.
-
Piroxicam-β-cyclodextrin: a GI safer piroxicam.Curr Med Chem. 2013;20(19):2415-37. doi: 10.2174/09298673113209990115. Curr Med Chem. 2013. PMID: 23394552 Free PMC article. Review.
-
Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia.Cochrane Database Syst Rev. 2025 May 8;5(5):CD014585. doi: 10.1002/14651858.CD014585.pub2. Cochrane Database Syst Rev. 2025. PMID: 40337979
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical